Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard Growth Index Fund ETF — how do they compare? Neurocrine Biosciences Inc trades at $156.06 (market cap $16.46B), while Vanguard Growth Index Fund ETF trades at $88.89. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | VUG | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $90.29 |
52-Week Low | $123.10 | $70.00 |
Enterprise Value | $16.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
Vanguard Growth ETF (VUG) trades at $88.87, down 0.35% today, with a bullish technical outlook supported by moving averages. The ETF shows strong institutional accumulation, with multiple firms increasing positions by over 500% in Q2 2026. Technical indicators show overbought RSI levels but strong trend momentum with ADX readings above 30.
VUG offers exposure to large-cap growth stocks with historical outperformance versus the S&P 500. Risks include growth stock volatility and concentration in technology sectors. The ETF remains attractive for long-term investors seeking growth exposure, though current overbought conditions suggest potential for near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
